NASDAQ:OCDX - Ortho Clinical Diagnostics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $24.55
  • Forecasted Upside: 11.02 %
  • Number of Analysts: 12
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 11 Buy Ratings
  • 0 Strong Buy Ratings
$22.11
▲ +0.39 (1.80%)
1 month | 3 months | 12 months
Get New Ortho Clinical Diagnostics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OCDX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OCDX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$24.55
▲ +11.02% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Ortho Clinical Diagnostics in the last 3 months. The average price target is $24.55, with a high forecast of $27.00 and a low forecast of $20.00. The average price target represents a 11.02% upside from the last price of $22.11.

Buy

The current consensus among 12 investment analysts is to buy stock in Ortho Clinical Diagnostics.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/24/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/21/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/19/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/18/2020
  • 0 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/18/2021
  • 0 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/17/2021
  • 0 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/16/2021

Latest Recommendations

  • 0 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/6/2021Credit Suisse GroupBoost Price TargetOutperform$21.00 ➝ $23.00High
i
5/6/2021Morgan StanleyBoost Price TargetOverweight$24.00 ➝ $25.00High
i
3/2/2021BarclaysInitiated CoverageOverweight$24.00Medium
i
2/22/2021Evercore ISIInitiated CoverageOutperform$26.00High
i
2/22/2021Wolfe ResearchInitiated CoverageMarket PerformMedium
i
2/22/2021Piper SandlerInitiated CoverageOverweight$27.00Medium
i
2/22/2021JPMorgan Chase & Co.Initiated CoverageOverweight$25.00Medium
i
2/22/2021Morgan StanleyInitiated CoverageOverweight$24.00Medium
i
2/22/2021UBS GroupInitiated CoverageBuy$23.00Medium
i
2/22/2021CitigroupInitiated CoverageBuy$20.00Medium
i
2/22/2021Credit Suisse GroupInitiated CoverageOutperform$21.00Medium
i
2/22/2021The Goldman Sachs GroupInitiated CoverageBuy$27.00Medium
i
2/22/2021Bank of AmericaInitiated CoverageBuy$23.00Medium
i
2/22/2021HC WainwrightInitiated CoverageBuy$27.00Medium
i
Rating by Y. Chen at HC Wainwright
(Data available from 6/17/2016 forward)
Ortho Clinical Diagnostics logo
Ortho Clinical Diagnostics Holdings plc engages in the vitro diagnostics business worldwide. The company offers automated instruments; and assays, reagents, and other consumables that are used by these instruments to generate test results. Its solutions include clinical chemistry and immunoassay instruments and tests to detect and monitor disease progression across a spectrum of therapeutic areas, including COVID-19 antibody and antigen tests; and immunohematology instruments and tests for blood typing to ensure patient-donor compatibility in blood transfusions, as well as donor screening instruments and tests for blood and plasma screening for infectious diseases. The company also engages in contract manufacturing activities; and provides orthocare services. Its products are used in hospitals, laboratories, clinics, blood banks, and donor centers. The company was founded in 1939 and is headquartered in Raritan, New Jersey.
Read More

Today's Range

Now: $22.11
$21.74
$22.27

50 Day Range

MA: $20.21
$18.15
$22.31

52 Week Range

Now: $22.11
$15.14
$22.99

Volume

25,574 shs

Average Volume

1,322,245 shs

Market Capitalization

$4.92 billion

P/E Ratio

76.24

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Ortho Clinical Diagnostics?

The following sell-side analysts have issued reports on Ortho Clinical Diagnostics in the last twelve months: Bank of America Co., Barclays PLC, Citigroup Inc., Credit Suisse Group AG, Evercore ISI, HC Wainwright, JPMorgan Chase & Co., Morgan Stanley, Piper Sandler, The Goldman Sachs Group, Inc., UBS Group AG, and Wolfe Research.
View the latest analyst ratings for OCDX.

What is the current price target for Ortho Clinical Diagnostics?

11 Wall Street analysts have set twelve-month price targets for Ortho Clinical Diagnostics in the last year. Their average twelve-month price target is $24.55, suggesting a possible upside of 13.0%. The Goldman Sachs Group, Inc. has the highest price target set, predicting OCDX will reach $27.00 in the next twelve months. Citigroup Inc. has the lowest price target set, forecasting a price of $20.00 for Ortho Clinical Diagnostics in the next year.
View the latest price targets for OCDX.

What is the current consensus analyst rating for Ortho Clinical Diagnostics?

Ortho Clinical Diagnostics currently has 1 hold rating and 11 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe OCDX will outperform the market and that investors should add to their positions of Ortho Clinical Diagnostics.
View the latest ratings for OCDX.

What other companies compete with Ortho Clinical Diagnostics?

How do I contact Ortho Clinical Diagnostics' investor relations team?

Ortho Clinical Diagnostics' physical mailing address is 1001 ROUTE 202, RARITAN NJ, 08869. The company's listed phone number is 908-218-8000 and its investor relations email address is [email protected] The official website for Ortho Clinical Diagnostics is www.orthoclinicaldiagnostics.com.